EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Overcoming platinum resistance by the disulfiram metabolite CuET in novel preclinical models of human carcinomas

Stefanos Arampatzis iD, Tereza Buchtová iD, Jirina Bartkova, Marie Lund Bay, Christoffer Lynge Halvorsen iD, Zuzana Machacova, Zdenek Skrott, Martin Mistrik iD, Ekaterina Dulina, Miguel Andujar-Sanchez, Estrid Høgdall, Tine Henrichsen Schnack und 9 weitere

Molecular Oncology · 04.11.2026

DOI: 10.1002/1878-0261.70356 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 04.11.2026. Verfasst von Stefanos Arampatzis und 20 weiteren Autor:innen. Beteiligte Einrichtung: Genome Integrity Group, Danish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: SALVAGE, Centrum för idrottsforskning, Kræftens Bekæmpelse.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Overcoming resistance to standard‐of‐care chemotherapy represents an unmet need in oncology. To help address this challenge, here we established and characterized a panel of human cisplatin‐resistant lung and breast cancer cell lines and patient‐derived organoids from high‐grade serous ovarian carcinomas (HGSOC), and show that platinum resistance can be overcome by treatment with diethyldithiocarbamate‐copper (CuET), a metabolite of the alcohol‐aversion drug disulfiram. All platinum‐resistant models remained sensitive to CuET, consistent with distinct cytotoxicity mechanisms: proteotoxic stress for CuET and DNA damage for cisplatin, respectively. Platinum adduct and DNA damage response analyses suggested diverse mechanisms of cisplatin resistance among our models. Considering potential CuET‐based therapies, our gene knock‐down and functional assays in preclinical models, complemented with immunohistochemical analysis of tissue samples from cohorts of triple‐negative breast cancer and HGSOC patients indicate that levels of metallothioneins, rather than NPL4 (the molecular target of CuET) warrant further evaluation as candidate biomarkers of CuET sensitivity. This dataset provides a resource of platinum‐resistant models of common carcinomas, identifies CuET as a compound overcoming such resistance and provides leads for predictive biomarker discovery, with potential clinical implications in oncology.

Schlagwörter

Stichwörter der Autor:innen

biomarkersbreast and ovarian cancerdisulfiram metabolitelungmetallothioneinplatinum resistance

Autor:innen und Institutionen

  • Genome Integrity Group, Danish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark.
  • Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Science for Life Laboratory, Karolinska Institute, Stockholm, Sweden.
  • Cancer Invasion and Resistance Group, Danish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark.
  • Faculty of Medicine and Dentistry, Institute of Molecular and Translational Medicine, Palacky University, Olomouc, Czech Republic.
  • Department of Pathology, Complejo Hospitalario Universitario Insular, Las Palmas, Gran Canaria, Spain.
  • Molecular Unit, Department of Pathology, Copenhagen University Hospital, Herlev and Gentofte Hospital, Denmark.

ORCID-Profile: Stefanos Arampatzis, Tereza Buchtová, Christoffer Lynge Halvorsen, Martin Mistrik, Robert Strauss, Jiri Bartek

Förderung

  • SALVAGE
  • Centrum för idrottsforskning
  • Kræftens Bekæmpelse
  • Danish National Research Foundation
  • Project OVACAN
  • Czech BioImaging
  • Cancerfonden
  • Novo Nordisk Foundation

Zitieren

APA

Arampatzis, S., Buchtová, T., Bartkova, J., Bay, M. L., Halvorsen, C. L., Machacova, Z., Skrott, Z., Mistrik, M., Dulina, E., Andujar-Sanchez, M., Høgdall, E., Schnack, T. H., Høgdall, C., Mosgaard, B. J., Boennelycke, M., Laursen, J. B., Jensen, A., Kjær, S. K., Kallunki, T., …, & Bartek, J. (2026). Overcoming platinum resistance by the disulfiram metabolite CuET in novel preclinical models of human carcinomas. Molecular Oncology. https://doi.org/10.1002/1878-0261.70356

Vancouver

Arampatzis S, Buchtová T, Bartkova J, Bay ML, Halvorsen CL, Machacova Z, et al. Overcoming platinum resistance by the disulfiram metabolite CuET in novel preclinical models of human carcinomas. Molecular Oncology. 2026. doi:10.1002/1878-0261.70356

BibTeX
@article{Arampatzis2026,
  author = {Arampatzis, Stefanos and Buchtová, Tereza and Bartkova, Jirina and Bay, Marie Lund and Halvorsen, Christoffer Lynge and Machacova, Zuzana and Skrott, Zdenek and Mistrik, Martin and Dulina, Ekaterina and Andujar-Sanchez, Miguel and Høgdall, Estrid and Schnack, Tine Henrichsen and Høgdall, Claus and Mosgaard, Berit Jul and Boennelycke, Marie and Laursen, Jacob Brink and Jensen, Allan and Kjær, Susanne K and Kallunki, Tuula and Strauss, Robert and Bartek, Jiri},
  title = {Overcoming platinum resistance by the disulfiram metabolite CuET in novel preclinical models of human carcinomas},
  journal = {Molecular Oncology},
  year = {2026},
  doi = {10.1002/1878-0261.70356}
}
Kostenlos starten →